Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of “Hold” by Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned a consensus recommendation of “Hold” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $19.40.

A number of research analysts recently commented on TBPH shares. BTIG Research cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. Weiss Ratings upgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. HC Wainwright lowered Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price objective for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Zacks Research upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Finally, JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th.

Theravance Biopharma Price Performance

Shares of NASDAQ:TBPH opened at $17.04 on Friday. The company’s fifty day moving average price is $16.95 and its 200-day moving average price is $16.62. The firm has a market capitalization of $884.72 million, a price-to-earnings ratio of 16.87 and a beta of 0.19. Theravance Biopharma has a one year low of $13.08 and a one year high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%.The company had revenue of $20.73 million for the quarter, compared to the consensus estimate of $22.49 million. As a group, equities research analysts expect that Theravance Biopharma will post 1.56 EPS for the current year.

Insider Buying and Selling

In other Theravance Biopharma news, major shareholder Eli Samaha sold 273,871 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the transaction, the insider directly owned 9,237,279 shares in the company, valued at $159,158,317.17. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the transaction, the senior vice president directly owned 232,457 shares in the company, valued at $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 350,011 shares of company stock worth $6,008,309 over the last quarter. Company insiders own 7.65% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC bought a new stake in Theravance Biopharma in the first quarter valued at approximately $2,076,000. Wedge Capital Management L L P NC bought a new stake in Theravance Biopharma during the 2nd quarter valued at $2,190,000. Precision Wealth Strategies LLC purchased a new stake in Theravance Biopharma during the 1st quarter valued at $1,019,000. Dimensional Fund Advisors LP grew its holdings in Theravance Biopharma by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock worth $15,960,000 after acquiring an additional 124,658 shares during the last quarter. Finally, Rangeley Capital LLC purchased a new position in shares of Theravance Biopharma in the first quarter valued at about $1,672,000. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.